Skip to main content

UBS Group AG

Position in LGND — Ligand Pharmaceuticals Inc

CIK 1610520 ZURICH, V8

Position in LGND

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$39,408,203
+$18,528,808 QoQ
Shares Held
124,674
+19.2% QoQ
Ownership
0.625%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#41
of 415 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 95% Shared 0% None 5%

Common Shares in LGND Over Time

Shares Held

Position Value (USD)

Derivatives in LGND

reported options exposure · as of Jun 30, 2021
CallValue
$1,180,710
CallShares
14,427
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,681,375 across 562 Biotechnology names. LGND ranks #44 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in LGND

Export CSV
32 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $39,408,203 124,674
2026-03-31 $20,879,395 104,580
2025-12-31 $27,049,677 143,067
2025-09-30 $19,837,198 111,986
2025-06-30 $3,809,416 33,510
2025-03-31 $3,200,039 30,436
2024-12-31 $2,904,300 27,105
2024-09-30 $1,150,734 11,497
2024-06-30 $3,268,107 38,786
2024-03-31 $2,416,904 33,063
2023-12-31 $1,358,908 19,027
2023-09-30 $414,406 6,916
2023-06-30 $582,207 8,075
2023-03-31 $86,873 1,181
2022-12-31 $110,888 1,660
2022-09-30 $30,999 360
2022-06-30 $59,776 670
2022-03-31 $3,519,138 31,284
2021-12-31 $4,150,029 26,868
2021-09-30 $3,753,556 26,942
2021-06-30 $1,262,440 9,623
2021-06-30 $1,180,710 9,000
2021-03-31 $2,439,199 16,000
2021-03-31 $572,296 3,754
2021-03-31 $11,631,931 76,300
2020-12-31 $519,228 5,221
2020-12-31 $3,321,628 33,400
2020-09-30 $495,663 5,200
2020-09-30 $459,823 4,824
2020-06-30 $847,710 7,579
2020-03-31 $315,459 4,338
2020-03-31 $763,559 10,500